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Summary
QUESTION UNDER STUDY: The frequency of severe
adverse drug reactions (ADRs) from psychotropic drugs
was investigated in hospitalised psychiatric patients in rela-
tion to their age. Specifically, the incidence of ADRs in pa-
tients up to 60 years was compared to that of patients older
than 60 years.
METHODS: Prescription rates of psychotropic drugs and
reports of severe ADRs were collected in psychiatric hos-
pitals in Switzerland between 2001 and 2010. The data
stem from the drug surveillance programme AMSP.
RESULTS: A total of 699 patients exhibited severe ADRs:
517 out of 28,282 patients up to 60 years (1.8%); 182 out of
11,446 elderly patients (1.6%, ns). Logistic regression ana-
lyses showed a significantly negative relationship between
the incidence of ADRs and patients’ age in general and
in particular for weight gain, extrapyramidal motor system
(EPMS) symptoms, increased liver enzymes and galactor-
rhoea. A significantly negative relationship was observed
for age and the dosages of olanzapine, quetiapine,
risperidone, valproic acid and lamotrigine. When compar-
ing age groups, frequency of ADRs was lower in general
for antipsychotic drugs and anticonvulsants, in particular
for valproic acid in the elderly. Weight gain was found
to be lower in the elderly for antipsychotic drugs, in par-
ticular for olanzapine. For the group of mood-stabilising
anticonvulsants (carbamazepine, lamotrigine and valproic
acid) the elderly exhibited a lower incidence of reported al-
lergic skin reactions.
CONCLUSION: The results suggest that for psychiatric
inpatients the incidence of common severe ADRs (e.g.,
weight gain or EPMS symptoms) arising from psychotrop-
ic medication decreases with the age of patients.
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Introduction
The overall consensus is that elderly psychiatric patients
are more prone to develop adverse drug reactions (ADRs)
than younger patients as a consequence of psychophar-
macological medication [1]. This is described in special
guidelines on the use of antipsychotics [2] (especially con-
cerning cardiovascular accidents) and of anticonvulsants
[3] in the elderly. However, actual scientific data on the fre-
quency of ADRs in relation to age are rather sparse.
Elderly persons with psychiatric disorders frequently suffer
from somatic diseases and may receive polypharmacy
more than younger patients. Thus, they may tend to devel-
op ADRs more frequently. On the other hand, physicians
possibly consider these special requirements of elderly psy-
chiatric patients and reduce the risks of ADRs in these pa-
tients. They may monitor their patients more intensively,
prescribe lower dosages or avoid high-risk drugs and dan-
gerous combinations. Indeed, several authors have emphas-
ised that psychotropic drugs are in general well tolerated by
the elderly [4], particularly lamotrigine [5], olanzapine [6],
quetiapine [7], risperidone [7] and valproic acid [8].
The present study aimed to verify the hypothesis that the
risk of ADRs increases with the age of patients. For this
purpose we used a large data sample from the international
AMSP drug surveillance programme (Arzneimittelsicher-
heit in der Psychiatrie – drug safety in psychiatry) [9]. The
programme records severe ADRs in patients from a large
age range who are hospitalised in psychiatric settings. It
also records the prescriptions of drugs and personal data
such as age, sex and diagnosis. The data were taken exclus-
ively from Swiss psychiatric hospitals and were collected
from 2001 to 2010.
The data allowed us to evaluate the frequency of ADRs of
psychotropic drugs in relation to the age of the patients and
to compare patients aged up to 60 years with those older
than 60 years. To the best of our knowledge, such an ana-
lysis had not previously been conducted.
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Method
Ethics committee
The ethics committee of the Ludwig Maximilian
University of Munich, the location of the AMSP main data
centre (up to 2011), had approved the analysis of the AMSP
data with a waiver of authorisation. The permission to use
the special data set from Swiss hospitals was given by the
publication commission consisting of the presidents of the
AMSP associations in Germany, Austria and Switzerland.
Data
The data stem from the international AMSP project initi-
ated at the Psychiatric University Hospital in Munich in
1993. Today it runs in 60 psychiatric hospitals in Germany,
Austria and the German-speaking part of Switzerland (12
hospitals). The data in the present study were collected
between 2001 and 2010 in selected wards (including ge-
rontopsychiatric wards) of psychiatric hospitals in Switzer-
land. The AMSP method is described in detail elsewhere
[9–11].
Briefly, the AMSP project comprises of two differing data
sets: One data set includes prescriptions of drugs, the age,
sex and primary diagnosis of patients receiving the drugs
as well as the number of inpatients monitored per year.
The second data set includes detailed information on severe
ADRs that were observed in the patients of the participat-
ing hospitals during psychotropic drug treatment. The med-
ical description of the ADRs was made by the treating
physician, and the association between the ADRs and the
medication was assessed by consensus of an expert com-
mittee (causality assessment). The present data comprise of
only data for severe ADRs with “probable” and “definite”
associations.
An ADR is rated as severe in the AMSP project if it (a) has
a significant impact on the course of treatment (e.g., if it is
life threatening or seriously endangers the patient’s health),
(b) considerably impairs everyday functioning, or (c) re-
quires the patient’s transfer to another department or ward
where more intensive or specialised care is provided [9, 10]
.The AMSP study protocol provides additional guidelines
based on each system or organic class and gives precise
definitions of ADRs [9, 10], for example increase in liver
enzymes >5 times the upper normal limit; allergic skin re-
action, if affecting the whole body or more than one body
part (e.g. face and arms) or if connected with general symp-
toms like fever and malaise; oedema if marked, lasting
more than one week and affecting special body parts as
face, lower or upper eyelid or requiring diuretic treatment;
galactorrhoea, if marked or accompanied by pain or tension
of the breast or gynecomastia. The definitions for weight
gain and extrapyramidal motor system (EPMS) symptoms
were changed in 2001, including ADR weight gain: weight
gain >10% of patient’s normal weight; EPMS symptoms:
malignant and catatonic neuroleptic syndrome, tardive dys-
kinesia, acute dystonia and Parkinsonism, of severely dis-
abling in everyday functioning; akathisia: grade 4 on the
Barnes akathisia rating scale; and all cases of Pisa syn-
drome and atypical dyskinesias. The AMSP definitions of
severe ADRs differ from the definition as given by the
Food and Drug Administration [12]. All ADRs analysed in
this study had been classified as severe.
Each individual case is reviewed by an expert committee
in detail. In national and international case conferences oc-
curring several times per year, disputable cases are dis-
cussed by experts of the participating sites, by drug safety
experts of pharmaceutical companies and by delegates of a
pharmaco-vigilance centre (University of Zurich, Switzer-
land) and drug regulating authorities (Germany).
The probability of a causal relationship (causality assess-
ment) is graded as follows: Possible: ADR not known or
alternative explanation more likely. Probable: ADR known
for drug in question, as well as time course and dosage in
accordance with previous experience, and alternative ex-
planation less likely. Definite: ADR “probable” plus re-
appearance after re-challenge with the drug [9, 10]. In cases
of drug combinations in which a pharmacodynamic / phar-
macokinetic interaction is held responsible for an ADR,
each drug is imputed. For the present analysis ADR rates
for different drugs or drug groups referred to all cases in
which drugs were imputed alone or in combination with
other drugs. Only data from hospitals with a minimum fre-
quency of 0.5% of reported ADRs were included in the cal-
culations.
Statistical method
Relative frequencies of ADRs were calculated by dividing
the number of patients who experienced ADRs by the num-
ber of all patients exposed to this particular psychotropic
medication. Two different statistical methods were used:
1. Logistic regression: To analyse the relationship
between the relative frequency of ADRs and age, the
relative frequency of ADRs for each year of age (15
years – 93 years) of the patients was plotted against
age, and logistic regression and cross table analyses
were calculated. Linear regression was used for the
analysis of the relation of doses of drugs and age.
2. Analysis of group means: The relative frequency of
ADRs was sub-divided into two groups (0–60 years
and 61–120 years), and 95% confidence intervals (CI)
were calculated for these groups using the Clopper
Pearson method [13], with α = 0.05; k = number of
patients with ADRs, n = number of patients. A
statistically significant difference between two relative
frequencies was defined as non-overlapping
confidence intervals of these two relative frequencies.
A marginal overlap was defined as a statistical trend.
The use of two different methods allowed us to generalise
the results across both statistical methods.
Results
Patient population
Table 1 describes the patient population. In the age group
up to 60 years, schizophrenia was the most common dia-
gnosis (45%); in the group above 60 years organic disor-
ders and schizophrenia (32% and 27%, respectively) were
the most frequent diagnostic categories. Antipsychotics
were the preferred class of medication in both age groups
(72% and 74%, respectively). Considering the whole group
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of patients, severe ADRs were assessed in 699 out of
39,728 patients (1.76%, CI 1.63–1.89). Within the group
up to 60 years the respective numbers were 517 cases with
ADRs out of 28,282 (1.82%; CI 1.68–1.99); in the elderly
the percentage of patients with reported ADRs was 1.60%
(182 ADR cases out of 11,446 patients, CI 1.37–1.84). The
difference between these age groups was not significant.
The regression models in figure 1a-f show that the dosages
of selected antipsychotics and anticonvulsants decreased
significantly with increasing age: lamotrigine (number of
patients: n = 1597, mean dose: 143 mg), olanzapine (n =
5248, mean: 16 mg), quetiapine (n = 6339, mean: 355 mg),
risperidone (n = 3183, mean: 3.4 mg) and valproic acid (n
= 8448, mean: 1298 mg), but not carbamazepine (n = 707,
mean: 659 mg). For these substances lower frequencies of
ADRs were found in the elderly (cf. fig. 3–5.)
Age and ADRs in general
As shown in fig. 2 the relative frequency of severe ADRs
due to psychotropic medication decreased with age. Ac-
cording to logistic regression and cross table analyses a sig-
nificant relation of ADRs and age was found. The risk of
developing severe ADRs in clinical settings decreased dur-
ing lifetime.
Age, ADRs and psychotropic medication
Figure 3 shows the frequency of ADRs in relation to the
number of patients receiving selected psychotropic medic-
ation, in particular the relative frequency of ADRs in the
younger patient group (≤60 y) and in the elderly (>60 y).
The relative frequency of reported ADRs for antipsychotics
and for anticonvulsants was significantly higher in young-
er patients than in the elderly: 1.8% versus 1.3% and 1.0%
versus 0.64% of the patients treated with these drugs, re-
spectively. Within the anticonvulsants, this statistical dif-
ference was also found for the substance valproic acid:
0.9% versus 0.42% ADRs. The confidence interval (CI)
values are given in the legend. With regard to minor tran-
quilisers, medicated patients >60 years showed a trend for
more ADRs than younger patients. In almost all cases, the
tranquilisers were imputed for ADRs in combination with
Figure 1a–f
Linear Regression Models of dosages of selected drugs in relation to age.
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other drugs. Comparisons with other drugs or classes of
drugs did not yield significant differences.
Selected ADRs
Table 2 shows the results of logistic regression and cross
table analyses for selected ADRs as observed in at least 20
patients. A minimum of n = 20 was chosen to ensure val-
id results in the regression analyses. Generally, the risk for
ADRs decreases significantly with age (cf also fig. 2) and
also for some particular ADRs, for example extrapyram-
idal motor system (EPMS) symptoms, galactorrhoea and
weight gain (according to both, regression analysis and
cross tables) and increased liver enzymes (according to re-
gression analysis). In contrast, the risk of developing deli-
rium increased with age (according to regression analysis),
and the risk of developing oedema also showed a corres-
ponding trend (according to cross table analysis). No rela-
tionship was found between age and the risk of developing
allergic skin reactions and hypotonia / collapse. Besides the
EPMS symptoms (including various single motor system
ADRs, e.g. Parkinsonism and tardive dyskinesia), weight
gain and allergic skin reactions were the ADRs observed
most often. Hence, the age dependency of the latter ADRs
will be described more in detail.
Weight gain
Regression analysis (table 2) revealed a highly significant
decrease in weight gain with age, to the extent that weight
gain was almost never found in patients >60 years. Ad-
ditional statistical analyses between age groups confirmed
that patients <30 years of age had the highest risk of de-
veloping weight gain (n = 6493, k = 41, relative frequency
= 0.63%,CI (0.45 – 0.86)), while patients aged between
30 and 60 years have a significantly lower risk of weight
gain (n = 21789 , k = 35 relative frequency = 0.16%,
CI [0.11–0.22]). Patients >60 years had the lowest risk of
weight gain (n = 11446, k = 4, relative frequency = 0.03%,
CI [0.01–0.09]) compared to both other groups. The use
of antipsychotic drugs was at least 75% in all three age
groups: 95% (0–30 years) versus 86% (31–60 years) versus
75% (over 60 years).
Figure 2
Linear Regression Model of the relative frequency of all ADRs over
age of patients (15–93 years).
Regression Model for the subgroup 31–93 years: y = – 0.02x + 2.3,
R² = 0.1 F = 8.1, p <0.01; for the subgroup 61–93 years: y = – 0.03
x + 2.0, R² = 0.1, F = 4.7, p <0.05.
Differences in weight gain could be found between elderly
and younger patients during treatment with psychotropic
substances in general, with antipsychotics as a class, and
with olanzapine (fig. 4). Weight gain was not found in
the elderly at all for quetiapine and risperidone, although
2060 and 953 elderly patients received quetiapine and
risperidone, respectively.
Regression analysis showed that weight gain during olan-
zapine treatment decreased significantly with age. This re-
lationship could not be explained by the differences in
dosages which showed no significant relation to age in the
group of patients with weight gain under olanzapine.
Allergic skin rash
As the regression analysis in table 2 shows, allergic skin re-
action was not related to the age of the patients in general.
However, for patients taking drugs out of the group of
mood-stabilising anticonvulsants, that is carbamazepine,
lamotrigine, and valproic acid, elderly patients had a stat-
istically significant lower incidence of reported allergic
skin reactions (fig. 5): 0.31% for patients up to 60 years
and 0.07% for those over 60 years. Furthermore, a respect-
ive trend was found for lamotrigine: 1.15% compared to
0.24%.
Discussion
The present data provide evidence that the incidence of
severe ADRs due to psychotropic medication decreases in
hospitalised psychiatric patients with increasing age of pa-
tients. The reported severe ADRs in clinical routine appear
to be less frequent in patients older than 60 years than in
younger patients, especially those up to 30 years. At first
glance, this finding is surprising and also counterintuitive.
Figure 3
Relative frequency of ADRs for different classes of psychotropic
drugs in patients ≤60 years and patients >60 years of age.
* significant difference
(k = number of patients with ADRs). Significant differences for
Antipsychotics:
Patients ≤60 years: n = 20283, k = 362; 1.78% CI (1.61 – 1.98)
Patients >60 years: n = 8432, k = 111; 1,32% CI (1.08 – 1.58)
Anticonvulsants:
Patients ≤60 years: n = 8032, k = 81; 1.00% CI (0.80 – 1.25)
Patients >60 years: n = 4093, k = 26; 0.64% CI (0.42 – 0.80)
Valproic acid:
Patients ≤60 years: n = 5320, k = 48; 0.90% CI (0.71 – 1.19)
Patients >60 years: n = 3128, k = 13; 0.42% CI (0.22 – 0.71)
A trend for patients with tranquilisers: patients ≤60 years: n = 7835,
k = 17; 0.22% CI (0.13–0.35), patients >60 years: n = 3572, k = 20;
0.56% CI (0.34–0.86).
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However, several factors may contribute to this effect, and
thus it is difficult to draw any causal inferences.
It is possible that elderly patients are administered different
medications than younger patients. The present data,
however, show that lower rates of ADRs in the elderly
were found for the same classes of psychotropic drugs (an-
tipsychotic drugs and anticonvulsants for ADRs in general
and antipsychotic drugs for weight gain) and for the same
psychotropic substances (valproic acid for ADRs in gener-
al and olanzapine for weight gain).
Furthermore, elderly patients could already have had ex-
perience with psychopharmacological treatment and its
ADRs. Their physicians might have avoided medication
that was not tolerated. In contrast, younger patients might
have received certain substances for the first time and thus
have reacted with various ADRs. This might be a factor
contributing to the lower rate of allergic skin reaction ob-
served in the older age group with mood-stabilising anti-
convulsants.
In addition, differences in dosages of medication could be
a relevant factor. Young patients received higher doses that
were associated with a higher frequency of ADRs. Indeed,
our results clearly demonstrate that physicians reduce the
dosages with increasing age of the patients (e.g., for olan-
zapine, quetiapine, and risperidone). The differences in the
dosages of antipsychotics are presumably responsible for
the decrease in EPMS symptoms with increasing age, an
adverse effect known to be dose-dependent [14].
In contrast, allergic skin rashes appear to be independent of
the recommended dosages of medication [15, 16]. There-
fore, the observation in our study that allergic skin rashes
occur more often in younger patients on mood-stabilising
anticonvulsants can hardly be explained by differences in
dosages between the age groups.
The relationship between weight gain and dosage of anti-
psychotics is controversial. Some studies have not repor-
ted any relationship [17], while others found a positive
relationship for risperidone [18], clozapine [19], and olan-
zapine, respectively [20]. However, clinically significant
metabolic changes seem to be rather independent of dosage
[20, 21]. In the current study, a weight gain of 10% and
more while on olanzapine and antipsychotics in general
was found more frequently in the group of younger patients
up to 60 years of age. A regression analysis of our data
showed that weight gain during medication with olanza-
pine significantly decreases with age. This relationship ap-
pears to be independent of dosage.
The method of the present study, which was that physicians
noted and reported ADRs and experts established whether
there was a relationship between ADRs and medication,
may have produced a bias in the data. Physicians may tend
to notice ADRs more easily in younger patients and more
readily assign unexpected somatic reactions to particular
Table 1: Patient population. Number of patients (n), percentage of patients in a particular subgroup and number of patients with (probable or definite) severe adverse drug
reactions (ADRs), psychiatric diagnoses and the most important classes of psychotropic medication.
Overall ≤60 years >60 years
n n % n %
Number of patients 39728 28282 100% 11446 100%
Female 19838 12956 46% 6882 60%
Patients with ADRs 699 517 1.8% 182 1.6%
Addiction (ICD 10: F1) 3462 2931 10% 531 5%
Affective disorders (ICD 10: F3) 9288 6367 23% 2921 26%
Neuroses / Personality dis. (ICD 10: F4.6) 4076 3364 12% 712 6%
Organic disorder (ICD 10: F0) 5167 1551 6% 3616 32%
Schizophrenia (ICD10: F2) 15692 12602 45% 3090 27%
Antidepressants 18744 12421 44% 6323 54%
Antipsychotics 28715 20283 72% 8432 74%
Anticonvulsants 12125 8032 28% 4093 36%
Antiparkinsonian drugs 5457 3633 13% 1824 16%
Hypnotics 3972 2482 9% 1490 13%
Lithium-Salts 2170 1726 6% 444 4%
Nootropics 1063 148 1% 915 8%
Tranquilisers 11407 7835 28% 3572 31%
Table 2: Logistic Regression and Cross Table Analyses of selected ADRs
Adverse effect k Significance
Logistic regression and cross tables
Change
All ADRs 699 p < 0.01 Decreasing
Allergic skin reactions 53 p > 0.05 ns None
Delirium 34 p < 0.05 (regression analysis) Increasing
EPMS 126 p < 0.05 Decreasing
Galactorrhoea 22 p < 0.01 Decreasing
Hypotonia / Collapse 23 p > 0.05 ns None
Increased liver enzymes 22 p < 0.05 (regression analysis) Decreasing
Oedema 27 p = 0.07 trend (cross table analysis) Increasing
Weight gain 80 p < 0.01 Decreasing
Statistical significance relates to both statistical methods, logistic regression and cross table analysis. When the data are significant according to one of the methods only it
is given in brackets.
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psychotropic substances. In contrast, it can be difficult to
establish an association between a psychotropic substance
and somatic symptoms in elderly patients with a variety
of somatic troubles. Such perceptual biases in the causal-
ity assessment (with selective reporting and general under-
reporting of ADRs) can hardly be avoided in the present
naturalistic study. However, the influence of age was found
to differ for various ADRs. For example, the relative fre-
quency of weight gain was lower in the elderly, whereas the
relative frequency of delirium increased with age and for
oedema a respective trend was found.
Figure 4
Relative frequency of weight gain for patients ≤60 years and
patients >60 years medicated with different psychotropic
substances.
* significant difference
Significant differences for all psychotropic substances (patients
≤60 years: n = 28282, k = 97, 0.26%, CI (0.21–0.34); patients
>60 years: n = 11446, k = 7, 0.06%, CI [0.01–0.09]), for
antipsychotics (patients ≤60 years: n = 20283, k = 69, 0.34% CI
(0.26 – 0.43); patients >60 years: n = 8432, k = 3, 0.04% CI
[0.01–0.10]), for olanzapine (patients ≤60 years: n = 4076, k = 43,
1.05% CI (0.76–1.42); patients >60 years: n = 1172, k = 2, 0.17%
CI (0.02–0.61)), quetiapine (patients ≤60 years: n = 4279, k = 12;
patients >60 years: n = 2060, k = 0) and risperidone (patients ≤60
years: n = 2230, k = 7; patients >60 years: n = 953, k = 0).
Figure 5
Relative frequency of allergic skin reactions for patients ≤60 years
and patients >60 years medicated with mood stabilizing
anticonvulsants (ACs).
Significant difference for the group of ACs (carbamazepine,
lamotrigine, valproate): 0.31% CI (0.21–0.51) for patients ≤60 years
(n = 6712, k = 21) and 0.07% CI (0.02–0.20) for those >60 years (n
= 4040, k = 3). A trend for lamotrigine (patients ≤60 years: 1.16 %;
CI (0.65–2.1), n = 866, k = 10; patients >60 years: 0.14%, CI
(0.01–0.7), n = 422, k = 1).
Our method of relating the frequency of reported ADRs to
the frequency of prescribed drugs has yielded plausible res-
ults from the AMSP project. Higher rates of the ADR in-
creased liver enzymes were found for clozapine in compar-
ison to other substances [22] in agreement with the literat-
ure [23–26], as well as of EPMS symptoms for risperidone
and haloperidol [27–29], and of weight gain for olanzapine
[29–33]. Another AMSP study [34] reported delirium dur-
ing treatment with tricyclics [35, 36] and low rates of
ADRs due to SSRIs [37–39]. Higher rates of allergic skin
reactions during treatment with carbamazepine and lamo-
trigine [10] were also reported [40, 41]. Although the meth-
od has some important shortcomings, it still corroborates
well-known effects and thus has proven to be a valid meth-
od for measuring and quantifying ADRs.
Although it may be considered a caveat that ours was a nat-
uralistic and not a controlled study, a strength of the study
is that the data represent the clinical reality of many differ-
ent psychiatric hospitals (university, state and private hos-
pitals) and various kinds of wards, including gerontopsy-
chiatric wards. Moreover, some of the results are based on
group means with multiple comparisons, which is at risk
of overestimating significant differences. However, since
two statistical methods were applied, linear regression and
comparisons of group means, it is possible to generalise the
results across statistical methods. To note, severe ADRs ac-
cording to the definition in the AMSP project differ from
ADRs according to other definitions, such as the FDA
definition [12].
There might be objective physiological differences in re-
sponse to psychopharmacological medication, such as an
altered tolerability of psychotropic medication in the eld-
erly or a slower and less obvious onset of ADRs. For ex-
ample, the neural responses of several receptors might de-
cline with age, for example pain receptors or dopaminergic
receptors. The ADRs weight gain and EPMS symptoms
were increased in schizophrenic adolescents on atypical an-
tipsychotics compared to adults [42, 43]. To the best of our
knowledge, similar data comparing adults and elderly pa-
tients are not available.
Only a few studies present data on age and ADRs of psy-
chopharmacological treatment. A good tolerability of
lamotrigine in elderly patients was found in several studies
[5, 16, 44]. Valproic acid was also observed to be well tol-
erated by patients over 60 years [8, 45], and weight gain
was not found [8]. One study comparing young and eld-
erly patients, which did not include the middle age group of
37–54 year olds, reported very low rates of ADRs for lamo-
trigine in the young group and higher values in the elderly
[46]. Our data showed that severe ADRs during treatment
with lamotrigine were not found in patients up to 30 years
of age, but were particularly frequent in the middle age
range (31–60 years) and relatively low in the elderly group
treated (0% versus 1.41% versus 0.14%, data not shown).
Two studies reported only a few ADRs of olanzapine in
elderly patients, and in particular no extrapyramidal side
effects [6, 47]. One epidemiologic study on elderly patients
found a general risk of metabolic effects with olanzapine
[48]. A good tolerability was reported for quetiapine and
risperidone in elderly psychiatric patients [4, 7]. In about
600 psychiatric patients aged over 65 years, Curran et al.
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[4] found that antipsychotic drugs were the class of medica-
tion mostly used in the elderly – in agreement with our data
– and that serious ADRs were rare. Cerebrovascular events
in elderly patients suffering from dementia and treated with
antipsychotic drugs as reported in the literature [2] are very
rare and were not observed in the present study.
So far, the evidence in the literature indicates that psycho-
pharmacological treatment seems to be rather well toler-
ated by elderly patients.
In conclusion, the present data suggest that under clinical
routine conditions in psychiatric hospitals, younger pa-
tients rather than elderly are at a higher risk of developing
common, severe ADRs (e.g., EPMS symptoms and weight
gain) due to treatment with psychotropic drugs. However,
this conclusion must still be proven by epidemiological and
controlled clinical studies in a large population over a wide
age range.
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Figures (large format)
Figure 1a–f
Linear Regression Models of dosages of selected drugs in relation to age.
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Figure 2
Linear Regression Model of the relative frequency of all ADRs over age of patients (15–93 years).
Regression Model for the subgroup 31–93 years: y = – 0.02x + 2.3, R² = 0.1 F = 8.1, p <0.01; for the subgroup 61–93 years: y = – 0.03 x + 2.0,
R² = 0.1, F = 4.7, p <0.05.
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Figure 3
Relative frequency of ADRs for different classes of psychotropic drugs in patients ≤60 years and patients >60 years of age.
* significant difference
(k = number of patients with ADRs). Significant differences for
Antipsychotics:
Patients ≤60 years: n = 20283, k = 362; 1.78% CI (1.61 – 1.98)
Patients >60 years: n = 8432, k = 111; 1,32% CI (1.08 – 1.58)
Anticonvulsants:
Patients ≤60 years: n = 8032, k = 81; 1.00% CI (0.80 – 1.25)
Patients >60 years: n = 4093, k = 26; 0.64% CI (0.42 – 0.80)
Valproic acid:
Patients ≤60 years: n = 5320, k = 48; 0.90% CI (0.71 – 1.19)
Patients >60 years: n = 3128, k = 13; 0.42% CI (0.22 – 0.71)
A trend for patients with tranquilisers: patients ≤60 years: n = 7835, k = 17; 0.22% CI (0.13–0.35), patients >60 years: n = 3572, k = 20; 0.56%
CI (0.34–0.86).
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Figure 4
Relative frequency of weight gain for patients ≤60 years and patients >60 years medicated with different psychotropic substances.
* significant difference
Significant differences for all psychotropic substances (patients ≤ 60 years: n = 28282, k = 97, 0.26%, CI (0.21–0.34); patients >60 years: n =
11446, k = 7, 0.06%, CI [0.01–0.09]), for antipsychotics (patients ≤60 years: n = 20283, k = 69, 0.34% CI (0.26 – 0.43); patients >60 years: n =
8432, k = 3, 0.04% CI [0.01–0.10]), for olanzapine (patients ≤60 years: n = 4076, k = 43, 1.05% CI (0.76–1.42); patients >60 years: n = 1172, k
= 2, 0.17% CI (0.02–0.61)), quetiapine (patients ≤60 years: n = 4279, k = 12; patients >60 years: n = 2060, k = 0) and risperidone (patients ≤60
years: n = 2230, k = 7; patients >60 years: n = 953, k = 0).
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Figure 5
Relative frequency of allergic skin reactions for patients ≤60 years and patients >60 years medicated with mood stabilizing anticonvulsants
(ACs).
Significant difference for the group of ACs (carbamazepine, lamotrigine, valproate): 0.31% CI (0.21–0.51) for patients ≤60 years (n = 6712, k =
21) and 0.07% CI (0.02–0.20) for those >60 years (n = 4040, k = 3). A trend for lamotrigine (patients ≤60 years: 1.16 %; CI (0.65–2.1), n = 866,
k = 10; patients >60 years: 0.14%, CI (0.01–0.7), n = 422, k = 1).
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